Pathology: hepatocell cancer (HCC); mHCC - (neo)adjuvant (NA); mHCC - 1st line (L1);
hepatocell cancer (HCC) | mHCC - (neo)adjuvant (NA) | mHCC - 1st line (L1) | ||
Wang, 2024 | Wang, 2024 | ORIENT-32, 2021 | ||
sintilimab | 3 | T1 | T1 | T1 |
Standard of Care (SoC) | 0 | T0 | T0 | |
sorafenib | 0 | T0 |